Lederfolin

Calcium Levofolinate, the active ingredient in Lederfolin, is a folate analog presented as an oral formulation for oral use. It supplies a reduced form of folic acid that bypasses dihydrofolate reductase, allowing DNA synthesis to resume and providing rescue therapy after high‑dose methotrexate, supporting chemotherapy regimens, and correcting folate deficiency in patients who need rapid folate repletion.

GNH USA supplies Lederfolin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lederfolin (calcium levofolinate) acts on folate metabolism pathways and is employed in several clinical settings. - Rescue therapy after high‑dose methotrexate: restores folate pools to reduce toxicity and protect normal cells. - Adjunct in cancer chemotherapy regimens: supports DNA synthesis in healthy tissues during antifolate treatment. - Treatment of folate deficiency: provides bioavailable reduced folate for patients with inadequate folate status.

Lederfolin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools. - Rash: mild skin erythema. - Headache: transient.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction. - Neutropenia: marked reduction in white blood cells. - Hepatic dysfunction: elevated liver enzymes. - Stevens‑Johnson syndrome: severe skin reaction.

When prescribing Lederfolin, clinicians should consider several safety precautions to minimize risk. - Renal function: assess baseline kidney function before initiation. - Hepatic function: monitor liver enzymes during therapy. - Concomitant antifolate agents: avoid overlapping high‑dose methotrexate without appropriate timing. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Drug interactions: review all concomitant medications for folate pathway interference. - Store at ambient temperature: keep in original container, protect from moisture and light.

Lederfolin can interact with other medicines, some of which require avoidance and others close monitoring.

Major Interactions (Avoid): - Trimethoprim‑sulfamethoxazole: may antagonize folate rescue effect. - Phenytoin or carbamazepine: can increase folate metabolism and reduce efficacy.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen): may affect renal clearance of folate. - Proton pump inhibitors: may alter gastrointestinal absorption. - High‑dose vitamin B9 supplements: may diminish need for rescue therapy.